Heartflow, Inc. (NASDAQ:HTFL – Get Free Report) CFO Vikram Verghese sold 29,714 shares of the business’s stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $50.06, for a total value of $1,487,482.84. Following the completion of the transaction, the chief financial officer directly owned 184,789 shares of the company’s stock, valued at $9,250,537.34. The trade was a 13.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Vikram Verghese also recently made the following trade(s):
- On Tuesday, September 15th, Vikram Verghese sold 668 shares of Heartflow stock. The stock was sold at an average price of $50.01, for a total transaction of $33,406.68.
- On Monday, September 14th, Vikram Verghese sold 4,593 shares of Heartflow stock. The shares were sold at an average price of $50.24, for a total transaction of $230,752.32.
- On Tuesday, September 8th, Vikram Verghese sold 6,640 shares of Heartflow stock. The shares were sold at an average price of $50.03, for a total transaction of $332,199.20.
- On Thursday, September 3rd, Vikram Verghese sold 27,540 shares of Heartflow stock. The stock was sold at an average price of $49.69, for a total transaction of $1,368,462.60.
- On Wednesday, September 2nd, Vikram Verghese sold 5,876 shares of Heartflow stock. The shares were sold at an average price of $50.60, for a total transaction of $297,325.60.
Heartflow Stock Performance
HTFL opened at $49.57 on Friday. The company has a fifty day moving average of $37.27 and a two-hundred day moving average of $31.57. The stock has a market capitalization of $4.31 billion and a price-to-earnings ratio of -27.09. Heartflow, Inc. has a fifty-two week low of $20.13 and a fifty-two week high of $51.78.
Analyst Ratings Changes
Several brokerages have recently weighed in on HTFL. Stifel Nicolaus upped their target price on Heartflow from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Friday, August 14th. Canaccord Genuity Group boosted their price target on shares of Heartflow from $37.00 to $45.00 and gave the stock a “buy” rating in a report on Friday, August 14th. Robert W. Baird set a $45.00 price objective on shares of Heartflow in a report on Friday, August 14th. Freedom Capital upgraded shares of Heartflow to a “strong-buy” rating in a research report on Tuesday, June 30th. Finally, Piper Sandler reissued an “overweight” rating and set a $45.00 target price (up from $38.00) on shares of Heartflow in a research note on Friday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $44.88.
Read Our Latest Analysis on HTFL
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in HTFL. XXEC Inc. acquired a new position in Heartflow during the second quarter worth about $2,524,764,000. BlackRock Inc. acquired a new stake in Heartflow in the 2nd quarter valued at about $152,502,000. Bamco Inc. NY purchased a new position in Heartflow in the 2nd quarter worth approximately $94,625,000. Jupiter Topco LLC purchased a new position in Heartflow in the 2nd quarter worth approximately $70,983,000. Finally, Janus Henderson Group PLC boosted its holdings in shares of Heartflow by 152.0% during the 1st quarter. Janus Henderson Group PLC now owns 2,180,976 shares of the company’s stock worth $53,063,000 after purchasing an additional 1,315,416 shares during the last quarter.
About Heartflow
Heartflow, Inc is a medical technology company that develops artificial intelligence and imaging solutions for the diagnosis and management of coronary artery disease. Its platform analyzes data from coronary computed tomography angiography (CCTA) scans to create personalized, three-dimensional models of a patient’s coronary arteries.
The company’s primary offering, Heartflow Analysis, is designed to provide noninvasive estimates of fractional flow reserve derived from computed tomography (FFRCT).
Featured Stories
- Five stocks we like better than Heartflow
- Aeluma’s Selloff Could Be Setting Up Its Next Big Move
- Crypto Bill Stalls, Smart Money Calls: Time to Buy the Dip?
- The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks
- The Fed’s Rate Hike Could Backfire If Oil Prices Collapse
Receive News & Ratings for Heartflow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heartflow and related companies with MarketBeat.com's FREE daily email newsletter.
